M. N. Dudley, J. Loutit, and D. C. Griffith, Aerosol antibiotics: considerations in pharmacological and clinical evaluation, Curr. Opin. Biotechnol, vol.19, pp.637-643, 2008.

L. B. Palmer, Aerosolized antibiotics in the intensive care unit, Clin. Chest Med, vol.32, pp.559-574, 2011.

T. Velkov, N. Rahim, Q. Zhou, H. Chan, and J. Li, Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead, Adv. Drug Deliv. Rev, vol.85, pp.65-82, 2015.

J. Brillault, W. V. De-castro, and W. Couet, Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model, Antimicrob. Agents Chemother, vol.54, pp.543-545, 2010.

F. Tewes, J. Brillault, B. Lamy, P. O'connell, J. Olivier et al., Ciprofloxacin-loaded inorganic-organic composite microparticles to treat bacterial lung infection, Mol. Pharm, vol.13, pp.100-112, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01373710

S. Marchand, N. Grégoire, J. Brillault, I. Lamarche, P. Gobin et al., Biopharmaceutical characterization of nebulized antimicrobial agents in rats. 4. Aztreonam, vol.60, pp.3196-3198, 2016.

S. Marchand, P. Gobin, J. Brillault, S. Baptista, C. Adier et al., Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats, Antimicrob. Agents Chemother, vol.54, pp.3702-3707, 2010.

R. Wilson, T. Welte, E. Polverino, A. Soyza, H. Greville et al., Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study, Eur. Respir. J, vol.41, pp.1107-1115, 2013.

A. V. Gontijo, J. Brillault, N. Gregoire, I. Lamarche, P. Gobin et al., Journal of Controlled Release, vol.271, pp.118-126, 2018.

S. Marchand, Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin, Antimicrob. Agents Chemother, vol.58, pp.3942-3949, 2014.

S. Chono, H. Suzuki, K. Togami, and K. Morimoto, Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections, Drug Dev. Ind. Pharm, vol.37, pp.367-372, 2011.

R. Osman, P. L. Kan, G. Awad, N. Mortada, A. E. El-shamy et al., Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity, Int. J. Pharm, vol.449, pp.44-58, 2013.

D. J. Serisier, D. Bilton, A. Soyza, P. J. Thompson, J. Kolbe et al., Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial, Thorax, vol.68, pp.812-817, 2013.

J. P. Wong, H. Yang, K. L. Blasetti, G. Schnell, J. Conley et al., Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection, J. Control. Release, vol.92, pp.265-273, 2003.

M. Xiong, Y. Bao, X. Yang, Y. Zhu, and J. Wang, Delivery of antibiotics with polymeric particles, Adv. Drug Deliv. Rev, vol.78, pp.63-76, 2014.

H. X. Ong, F. Benaouda, D. Traini, D. Cipolla, I. Gonda et al., In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation, Eur. J. Pharm. Biopharm, vol.86, pp.83-89, 2014.

B. Paul, S. David, C. David, and B. Jim, Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation In healthy volunteers and non-cystic bronchiectasis patients, B49. Bronchiectasis: Cystic Fibrosis and Beyond, p.3192, 2010.

H. Stass, J. Nagelschmitz, S. Willmann, H. Delesen, A. Gupta et al., Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study, Clin. Drug Invest, vol.33, pp.419-427, 2013.

J. Brillault, F. Tewes, W. Couet, and J. C. Olivier, In vitro biopharmaceutical evaluation of ciprofloxacin/metal cation complexes for pulmonary administration, Eur. J. Pharm. Sci, vol.97, pp.92-98, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01416565

F. Tewes, O. L. Gobbo, C. Ehrhardt, and A. M. Healy, Amorphous calcium carbonate based-microparticles for peptide pulmonary delivery, ACS Appl. Mater. Interfaces, vol.8, pp.1164-1175, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01375596

R. Vanbever, J. D. Mintzes, J. Wang, J. Nice, D. Chen et al., Formulation and physical characterization of large porous particles for inhalation, Pharm. Res, vol.16, pp.1735-1742, 1999.

M. R. Marques, R. Loebenberg, and M. Almukainzi, Simulated Biological Fluids with Possible Application in Dissolution, Dissolution Technologies, vol.18, 2011.

R. Roosendaal, I. A. Bakker-woudenberg, M. Van-den-berghe-van-raffe, J. C. Vinkvan-den, M. F. Berg et al., Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats, Antimicrob. Agents Chemother, vol.31, pp.1809-1815, 1987.

R. Zhang, S. N. Ghosh, D. Zhu, P. E. North, B. L. Fish et al., Structural and functional alterations in the rat lung following whole thoracic irradiation with moderate doses: injury and recovery, Int. J. Radiat. Biol, vol.84, pp.487-497, 2008.

M. I. Amaro, F. Tewes, O. Gobbo, L. Tajber, O. I. Corrigan et al., Formulation, stability and pharmacokinetics of sugar-based salmon calcitoninloaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation, Int. J. Pharm, vol.483, pp.6-18, 2015.

H. A. Al-hosney, S. Carlos-cuellar, J. Baltrusaitis, and V. H. Grassian, Heterogeneous uptake and reactivity of formic acid on calcium carbonate particles: a Knudsen cell reactor, FTIR and SEM study, Phys. Chem. Chem. Phys, vol.7, pp.3587-3595, 2005.

Y. Politi, T. Arad, E. Klein, S. Weiner, and L. Addadi, Sea urchin spine calcite forms via a transient amorphous calcium carbonate phase, Science, vol.306, pp.1161-1164, 2004.

A. Al-sawalmih, C. Li, S. Siegel, P. Fratzl, and O. Paris, On the stability of amorphous minerals in lobster cuticle, Adv. Mater, vol.21, pp.4011-4015, 2009.

I. Turel, P. Bukovec, and M. Quirós, Crystal structure of ciprofloxacin hexahydrate and its characterization, Int. J. Pharm, vol.152, pp.59-65, 1997.

G. Wu, G. Wang, X. Fu, and L. Zhu, Synthesis, crystal structure, stacking effect and antibacterial studies of a novel quaternary copper (II) complex with quinolone, Molecules, vol.8, pp.287-296, 2003.

A. Grillon, F. Schramm, M. Kleinberg, and F. , Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies, PLoS One, vol.11, p.156690, 2016.

D. Macdonald, L. Cuthbertson, C. Doherty, S. Campana, N. Ravenni et al., Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?, J. Antimicrob. Chemother, vol.65, pp.2373-2375, 2010.

H. Mulcahy, L. Charron-mazenod, and S. Lewenza, Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms, PLoS Pathog, vol.4, p.21, 2008.

M. N. Martinez, M. G. Papich, and G. L. Drusano, Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target, Antimicrob. Agents Chemother, vol.56, pp.2795-2805, 2012.

N. J. Onufrak, A. Forrest, and D. Gonzalez, Pharmacokinetic and pharmacodynamic principles of anti-infective dosing, Clin. Ther, vol.38, pp.1930-1947, 2016.

N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, and O. Ciofu, Antibiotic resistance of bacterial biofilms, Int. J. Antimicrob. Agents, vol.35, pp.322-332, 2010.

H. Stass, H. Delesen, J. Nagelschmitz, and D. Staab, Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study, J. aerosol Med. Pulm. Drug Deliv, vol.28, pp.106-115, 2014.

M. C. Gaspar, N. Grégoire, J. J. Sousa, A. A. Pais, I. Lamarche et al., Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres, Eur. J. Pharm. Sci, vol.93, pp.184-191, 2016.

S. A. Breda, A. F. Jimenez-kairuz, R. H. Manzo, and M. E. Olivera, Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives, Int. J. Pharm, vol.371, pp.106-113, 2009.

S. Zakelj, K. Sturm, and A. Kristl, Ciprofloxacin permeability and its active secretion through rat small intestine in vitro, Int. J. Pharm, vol.313, pp.175-180, 2006.

A. Capelli, M. Lusuardi, C. G. Cerutti, and C. F. Donner, Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders, Am. J. Respir. Crit. Care Med, vol.155, pp.249-253, 1997.

J. O'gorman and H. Humphreys, Application of copper to prevent and control infection, J. Hosp. Infect, vol.81, pp.217-223, 2012.

K. Midander, P. Cronholm, H. L. Karlsson, K. Elihn, L. Möller et al., Surface characteristics, copper release, and toxicity of Nano-and micrometer-sized copper and copper (II) oxide particles: a cross-disciplinary study, Small, vol.5, pp.389-399, 2009.

E. N. Herken, E. Kocamaz, M. B. Kucukatay, H. Vural, H. Demirin et al., Ceruloplasmin, copper, selenium, iron, zinc, and manganese levels in normal and sulfite oxidase deficient rat plasma: effects of sulfite exposure, Biol. Trace Elem. Res, vol.123, pp.202-210, 2008.

M. Veenendaal, X. Zhang, A. Lemmens, and A. Beynen, Liver and plasma copper concentrations in rats fed diets containing various proteins, Biol. Trace Elem. Res, vol.34, pp.213-218, 1992.

G. E. Lester, C. J. Vanderwiel, T. K. Gray, and R. V. Talmage, Vitamin D deficiency in rats with normal serum calcium concentrations, Proc. Natl. Acad. Sci, vol.79, pp.4791-4794, 1982.

E. Table and V. Table, Dietary Reference Intakes for Vitamin a, Vitamin K, Arsenic, 2001.

D. E. Geller, P. A. Flume, D. Staab, R. Fischer, J. S. Loutit et al., Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa, Am. J. Respir. Crit. Care Med, vol.183, pp.1510-1516, 2011.

B. Lamy, Journal of Controlled Release, vol.271, pp.118-126, 2018.